	US 11,938,194 B2
	Cysteine mutated antibodies for conjugation
Andrew Waight, Bothell, WA (US); Chris Leiske, Bothell, WA (US); Travis Biechele, Bothell, WA (US); Django Sussman, Bothell, WA (US); Patrick Burke, Bothell, WA (US); and Jocelyn Leiske, Bothell, WA (US)
Assigned to SEAGEN INC., Bothell, WA (US)
Appl. No. 16/483,025
Filed by SEAGEN INC., Bothell, WA (US)
PCT Filed Feb. 28, 2018, PCT No. PCT/US2018/020206 § 371(c)(1), (2) Date Aug. 1, 2019, PCT Pub. No. WO2018/160683, PCT Pub. Date Sep. 7, 2018.
Claims priority of provisional application 62/465,129, filed on Feb. 28, 2017.
Claims priority of provisional application 62/561,151, filed on Sep. 20, 2017.
Prior Publication US 2022/0175947 A1, Jun. 9, 2022
Int. Cl. A61K 47/68 (2017.01); C07K 16/18 (2006.01)

CPC A61K 47/6829 (2017.08) [A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); C07K 16/18 (2013.01); C07K 2317/524 (2013.01)]

15 Claims

1. An antibody drug conjugate comprising an antibody comprising a heavy chain constant region in which position 295 by EU numbering is occupied by cysteine conjugated to a drug via the cysteine, wherein the heavy chain constant region has the sequence of any one of SEQ ID NOS:5-12 provided the C-terminal lysine can be absent.